<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04291222</url>
  </required_header>
  <id_info>
    <org_study_id>IBS-AngelV1.0</org_study_id>
    <nct_id>NCT04291222</nct_id>
  </id_info>
  <brief_title>Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD</brief_title>
  <official_title>Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lifetech Scientific (Shenzhen) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lifetech Scientific (Shenzhen) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study on feasibility, efficacy and safety of IBS ® for implantation in the
      PDA in duct-dependent cyanotic CHD, and its objective is to investigate the feasibility,
      safety and efficacy of iron resorbable stent implantation in the PDA as initial palliation of
      cyanotic CHD with duct-dependent PBF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study type: Interventional, prospective, single arm, investigator initiated Study population:
      10 patients Primary purpose: Treatment Follow up: Review at 1 month and thereafter 3 monthly
      (clinical examination and echocardiography for stent patency, SaO2 measurement. Serum Iron
      and Ferritin levels will be measured before procedure and at follow ups. From 6 months
      onwards the patients will be assessed for the need of repeat catheterization with a view of
      surgery or for continued observation.

      Study endpoints: 9 months post implant or the following: 1)Patients are subjected for
      surgical repair of CHD; 2)Death before surgical repair; 3)Unplanned re-intervention with
      additional stenting procedure.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 11, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants for surgical repair of CHD</measure>
    <time_frame>9 months</time_frame>
    <description>Patients are subjected for surgical repair of CHD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Unplanned re-intervention</measure>
    <time_frame>9 months</time_frame>
    <description>Unplanned re-intervention with additional stenting procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>9 months</time_frame>
    <description>Death before surgical repair</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Patent Ductus Arteriosus</condition>
  <condition>Duct-dependent Cyanotic Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>IBS implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of IBS in PDA in duct-dependent cyanotic CHD</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Iron biocorrodable coronary scaffold system</intervention_name>
    <description>Implantation of Iron biocorrodable coronary scaffold system</description>
    <arm_group_label>IBS implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weight &gt;3.0 kg

          -  Age &lt;3 months

          -  Patients with uncomplicated PDA morphology (the PDA is not tortuous i.e. relatively
             straight

        Exclusion Criteria:

          -  Weight &lt;3 kg, age &gt;3 months

          -  Angiographic criteria-tortuous PDA

          -  Family history of diseases related to iron overload or iron disorder e.g. hereditary
             hemochromatosis

          -  Other severe congenital anomalies with life expectancy &lt;12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Jantung Negara</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 28, 2020</study_first_submitted>
  <study_first_submitted_qc>February 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

